NEKTAR THERAPEUTICS

NKTR
Delayed Quote. Delayed  - 08/07 04:00:00 pm
21.85USD +1.58%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2019 2020
Net sales1 115145
EBITDA1 -427-478
Operating profit (EBIT)1 -440-504
Operating Margin -384%-349%
Pre-Tax Profit (EBT)1 -440-522
Net income1 -441-522
Net margin -384%-361%
EPS2 -2,52-2,89
Dividend per Share2 --
Last update 02/27/202008/07/2020
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: December 2019 2020
Net Debt 153-
Net Cash position --
Leverage (Debt / EBITDA) -0,36x-
Free Cash Flow1 -355-413
ROE (Net Profit / Equities) -28,2%-47,5%
Shareholders' equity1 1 5611 100
ROA (Net Profit / Asset) -21,4%-34,9%
Assets1 2 0641 498
Book Value Per Share2 7,965,72
Cash Flow per Share --
Capex1 26,313,0
Capex / Sales 22,9%8,99%
Last update 02/27/202008/07/2020
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 3 889 M $ -
Valuation 2020e 2021e
P/E ratio (Price / EPS) -7,57x -8,90x
Capitalization / Revenue 26,9x 23,2x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,82x 5,77x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) -349% -268%
Operating Leverage (Delta EBIT / Delta Sales) - 0,66x
Net Margin (Net Profit / Revenue) -361% -256%
ROA (Net Profit / Asset) -34,9% -41,1%
ROE (Net Profit / Equities) -47,5% -61,8%
Rate of Dividend - -
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   8,99% 13,2%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) 10,4x 6,24x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend